Login to Your Account



Genzyme Regains Synvisc Rights From Wyeth For $121M Up Front

By Aaron Lorenzo


Friday, November 5, 2004
The Cambridge, Mass.-based company entered an agreement with Wyeth Pharmaceuticals to buy back rights for the osteoarthritis product in the U.S. and five European countries. As a result, Genzyme will receive all end-user revenue in those territories for Synvisc (hylan G-F 20), the top-selling viscosupplementation product for pain due to osteoarthritis of the knee in the U.S. and Canada. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription